Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Pluristyx, Inc.

News headline image
Pluristyx and Solesis Launch First-of-its-Kind PluriForm™-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
CORRECTION: Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions
From Pluristyx, Inc.
Via GlobeNewswire
News headline image
Stem Genomics Announces Partnership with Pluristyx, Leading One-Stop-Shop Solution Provider for High-Quality Cell-Based Therapies
From Pluristyx, Inc.
Via Business Wire
News headline image
Pluristyx and the Advanced Regenerative Manufacturing Institute to Commercialize Clinical-Grade Stem Cells
From Pluristyx, Inc.
Via Business Wire
News headline image
Pluristyx and Accelerated Biosciences Announce Availability of Clinical-Grade Immune-Privileged Human Trophoblast Stem Cells (hTSCs)
From Pluristyx, Inc.
Via Business Wire
News headline image
Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells
From Pluristyx, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.